$3.96 Billion is the total value of Bpifrance SA's 7 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CSTM | CONSTELLIUM NVcl a | $240,990,000 | +5.1% | 16,393,903 | 0.0% | 6.08% | -85.4% | |
| FTI | TECHNIPFMC PLC | $188,564,000 | -19.5% | 24,688,691 | 0.0% | 4.76% | -88.8% | |
| CRTO | CRITEO S Aspons ads | $94,422,000 | +69.3% | 2,718,752 | 0.0% | 2.38% | -76.4% | |
| CLLS | CELLECTISspons ads | $8,604,000 | -25.3% | 425,726 | 0.0% | 0.22% | -89.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CRITEO S A | 20 | Q3 2023 | 10.1% |
| TECHNIPFMC PLC | 13 | Q4 2021 | 68.1% |
| STELLANTIS NV | 11 | Q3 2023 | 90.9% |
| CONSTELLIUM NV | 11 | Q2 2021 | 41.6% |
| SEQUANS COMMUNICATIONS S A | 11 | Q2 2021 | 5.8% |
| CELLECTIS S.A. | 10 | Q2 2023 | 2.3% |
| CONSTELLIUM NV | 9 | Q3 2023 | 8.3% |
| SEQUANSCOMMUNICATIONS S A | 9 | Q3 2023 | 0.5% |
| MILLENDO THERAPEUTICS INC | 8 | Q3 2020 | 1.8% |
| VECTIVBIO HOLDING AG | 8 | Q1 2023 | 0.8% |
View Bpifrance SA's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-06 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-11 |
View Bpifrance SA's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.